nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

INTRODUCTION: The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2. METHODS: Chemother...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Gajra, Ajeet, Karim, Nagla Abdel, Mulford, Deborah A., Villaruz, Liza Cosca, Matrana, Marc Ryan, Ali, Haythem Y., Santos, Edgardo S., Berry, Tymara, Ong, Teng Jin, Sanford, Alexandra, Amiri, Katayoun, Spigel, David R.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2018
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6066533/
https://ncbi.nlm.nih.gov/pubmed/30087850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00253
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires